reviewAnnals of NeurologyMay 9, 2017Closed access

Chemotherapy‐induced peripheral neuropathy: A current review

NPNathan P. StaffAGAnna GrisoldWGWolfgang GrisoldAJAnthony J. Windebank

Mayo Clinic in Arizona · Medical University of Vienna · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol…

Citation impact

866
total citations
FWCI
21.00
Percentile
100%
References
115
Citations per year

Authors

4

Topics & keywords

Topics
Keywords
  • Chemotherapy-induced peripheral neuropathy
  • Peripheral neuropathy
  • Medicine
  • Chemotherapy
  • Peripheral
  • Current (fluid)
  • Oncology
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding